,i  #aai? ,,congress  #a/ ,session  ,h4 
,r4 #edae  ,,9 ,,! ,,h\se ,,(           
,,repres5tatives  ,septemb] #af1        
#bjbe,mr4 ,v9dman 7= himself & ,mr4     
,baumg>tn]7 introduc$ ! foll[+ bill2 :i*
 0 ref]r$ to ! ,committee on ,en]gy &   
,comm]ce1 & 9 addition to ! ,committee  
on ! ,judici>y1 = a p]iod to be         
subsequ5tly det]m9$ by ! ,speak]1 9 ea* 
case = consid]ation ( su* provisions z  
fall )9 ! jurisdiction ( ! committee    
conc]n$  ,a ,,bill  ,to am5d !          
,controll$ ,sub/ances ,act to p]man5tly 
s*$ule ! class ( b5zimidazole-opioids   
kn[n z nitaz5es1 & = o!r purposes4  #a4 
,%ort title ,?is ,act may be cit$ z !   
,nitaz5e ,control ,act ( #bjbe4  #b4    
,f9d+s ,congress f9ds ! foll[+3  7#a7   
#b-;,b5zylb5zimidazole opioids are a    
class ( syn!tic opioids fir/ syn!siz$ 9 
! #aiejs4 ,!y exhibit significant pot5cy
 at ! mu-opioid receptor1 ) "s sub/ances
 exce$+ ! pot5cy ( f5tanyl4  7#b7 ,!    
,drug ,en=cem5t ,adm9i/ration 7,,dea7   
has tempor>ily or p]man5tly s*$ul$      

multiple #b-;b5zylb5zimidazole opioid   
comp\nds "u ,s*$ule ,i ( ! ,controll$   
,sub/ances ,act due to _! high abuse    
pot5tial & lack ( accept$ m$ical use4   
7#c7 ,nitaz5es & relat$ comp\nds h em]g$
 9 ! illicit drug supply z design] drugs
 & contribute to ov]dose & fatal        
poison+s 9 ! ,unit$ ,/ates4  7#d7 ,a    
class-wide p]man5t s*$ul+ (             
#b-;b5zylb5zimidazole opioids is        
necess>y to preemptively address !      
prolif]ation ( new analogs1 /reaml9e    
en=cem5t1 & protect public heal?4  7#e7 
,! ,,halt ,f5tanyl ,act creat$ pa?ways =
 rese>* us+ ,s*$ule ,i controll$        
sub/ances :i* apply to s*$ul$ nitaz5es4 
#c4 ,s*$ule i classification ( nitaz5es 
7a7 ,am5dm5t ,section #bjb7;c7 ( !      
,controll$ ,sub/ances ,act 7#ba         
,u4,s4,c4 #hab7;c77 is am5d$ by add+ at 
! end ( ,s*$ule ,i ! foll[+3  7f7       
#b-;,b5zylb5zimidazole opioids1 commonly
 ref]r$ to z nitaz5es1 _! isom]s1 e/]s1 
e!rs1 salts & salts ( isom]s1 e/]s1 &   
e!rs1 includ+3 7#a7 ,is /ructurally     

relat$ to #b-;b5zylb5zimidazole ) !     
foll[+ modifications3  7,a7 ,at !       
#a-position1 sub/itution ) an alkyl l9k]
 connect$ to a sub/itut$ am9e gr\p      
conta9+ hydrog51 alkyl1 alk5yl1 &_/or   
het]o>yl gr\p 7e4g4 morphil9o1          
pyrrolid9o1 or pip]id9yl gr\ps71 :e!r or
 n fur!r sub/itut$4  7,b7 ,at !         
#b-position3 i4 ,replacem5t ( ! alkyl   
portion ( ! b5zyl gr\p ) a sub/itut$ or 
unsub/itut$ alkyl1 alkoxy1 c>bamates    
gr\p1 nitrog51 sulfur1 &_/or oxyg5      
atoms4 ii4 ,replacem5t ( ! ph5yl portion
 ( ! b5zyl gr\p ) an aryl or het]o>yl   
gr\p4  7,c7 ,sub/itution on ! ph5yl     
portion ( ! b5zimidazole r+ ) a hydrog5 
atom1 halog51 nitro1 cyano1 sub/itut$ or
 unsub/itut$ amide1 am9e1 alkyl1 alkoxy1
 aryl1 &_/or het]o>yl gr\ps4  7,d7 ,at !
 #f-position1 sub/itution ) hydrog51    
nitro1 trifluorome?yl1 me?oxy1          
trifluorome?oxy1 cyano1 & halog5 gr\ps42
 &  7#b7 ,exhibits agoni/ activity at ! 
mu-opioid receptor4 ,su* sub/ances      
include1 b are n limit$ to3 etonitaz5e1 

clonitaz5e1 metonitaz5e1 isotonitaz5e1  
protonitaz5e1 butonitaz5e1              
etodesnitaz5e1 flunitaz5e1 ,n-pyrrolid9o
 etonitaz5e1 ,n-dese?yl isotonitaz5e1 & 
,n-pip]id9yl etonitaz5e4  4  7b7        
,removal ( tempor>y /atus ,any sub/ance 
includ$ 9 ! am5dm5t to section #bjb7;c7 
( ! ,controll$ ,sub/ances ,act made by  
?is section t 0 tempor>ily s*$ul$ "u    
section #bja7;h7 ( ! ,controll$         
,sub/ances ,act %all be deem$ p]man5tly 
s*$ul$ & subject to ! requirem5ts (     
,s*$ule ,i z ( ! date ( enactm5t ( ?is  
,act4  7c7 ,rule ( con/ruction ,no?+ 9  
?is section or ! am5dm5ts made by ?is   
section %all be con/ru$ to au?orize !   
initiation ( new rese>* us+ sub/ances   
describ$ 9 ! am5dm5t made by subsection 
7a7 )\t prop] regi/ration & s*$ul+      
compliance4